Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional “3 + 7” intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial

ClinicalTrials.gov NCT06451861, Registered on June 11, 2024. https://clinicaltrials.gov/study/NCT06451861.